DEFENCE THERAPEUTICS INC
Commented by Fabian Lorenz on May 4th, 2023 | 08:10 CEST
Buy or sell? TUI, BASF and Defence Therapeutics
BASF share a buy or sell? Analyst opinions on the chemical giant diverge widely. The DAX-listed company has just reported quarterly figures, but it did not provide clarity about the prospects. However, some speculate on a forecast increase. Analysts have not commented on TUI for quite some time. After the turbulence surrounding the capital increase, new impulses are being sought, perhaps through a deal with the German government? There is plenty of impetus for rising prices at Defence Therapeutics. The biotech high-flyer of the past months is increasingly positioning itself as a partner to BioNTech, Moderna and Co - and perhaps even a takeover candidate.
Read
Commented by Armin Schulz on April 24th, 2023 | 08:30 CEST
BioNTech, Defence Therapeutics, Sartorius - Takeover fever in the biotech sector
In the past year, the NASDAQ Biotechnology Index took a severe beating until mid-June. In the meantime, an initial upward trend has developed, and the market is slowly heating up again because some biotech companies are still valued too cheaply. This is when the big players strike, such as Merck & Co, which recently bought Prometheus Biosciences for USD 10.8 billion. The buyer thus paid a premium of a whopping 75% on the previous day's closing price. The biotech start-up Tubulis has also agreed on a collaboration with Bristol-Myers Squibb that could bring more than USD 1 billion into the Munich-based company's coffers. Reason enough to take a look at three companies from the pharmaceutical and biotech sector.
Read
Commented by Stefan Feulner on April 19th, 2023 | 07:30 CEST
Morphosys, Defence Therapeutics, Moderna - The takeover wave keeps rolling
The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions to unmet medical needs. The most recent example is Pfizer's acquisition of Seagen for USD 43 billion. With Big Pharma sitting on filled coffers, this is likely to be just the beginning.
Read
Commented by Juliane Zielonka on April 14th, 2023 | 10:23 CEST
Bayer, Defence Therapeutics, Merck KGaA - Data power ensures high-speed commercialization
Germany is one of the best-funded countries in terms of research-based pharmaceutical companies. Nevertheless, Stefan Oelrich of Bayer Healthcare is critical. He thinks that data protection is putting the brakes on research. Defence Therapeutics, on the other hand, relies on enormous speed. Thanks to their data-driven ACCUM™ platform technology, they are helping mRNA vaccines, in particular, to achieve more intensive results. Pharmaceutical giant Merck is currently experiencing just how valuable data is in the US. In a Phase III clinical trial, the FDA stopped the enrolment of further patients, thus slowing down the research. The reason for the stop, however, is a serious one...
Read
Commented by André Will-Laudien on April 12th, 2023 | 10:34 CEST
Attention, biotech is back! Bayer, Defence Therapeutics, BioNTech - These stocks are breaking out!
For months the market did not care about biotech stocks. But now technical bottoms have been reached, and a rise is likely. In this context, the capital market interest rate is important: if it falls due to increased fears of recession, there is no stopping the biotechs because refinancing costs fall. Sentiment measurements over Easter showed that the risk bias of investors has also returned. If not now, then when, the moment is favorable! Shortlist the following stocks.
Read
Commented by Nico Popp on April 4th, 2023 | 17:04 CEST
Race against cancer: BioNTech, Bayer, Defence Therapeutics
BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.
Read
Commented by Stefan Feulner on March 20th, 2023 | 09:37 CET
Evotec, Defence Therapeutics, Morphosys - Movement in the biotech sector
Is a new wave of takeovers starting in the biotech sector? Already last year, acquisitions by Big Pharma were expected to increase, but these largely failed to materialize. However, this could accelerate in the current year. On the one hand, pharmaceutical companies, such as vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio; on the other hand, second-tier stocks are attractive targets due to the strong correction.
Read
Commented by Fabian Lorenz on March 16th, 2023 | 11:51 CET
Takeover speculation at Defence Therapeutics! What are BioNTech, Morphosys, and Evotec doing?
Defence Therapeutics is one of the biotech high flyers of the past months. The share has more than doubled since October. And this could be just the beginning. Operationally, things are going well, a strong partner has been acquired, and experts are speculating about a takeover. And what are the German biotechs doing? At BioNTech, it will be exciting at the end of March, because the Mainz-based company needs new blockbusters. At Morphosys, analysts recently saw further downside potential. Will a new management board bring about a turnaround? Evotec also had little positive to report. However, an AI investment in the hype surrounding ChatGPT is making headlines.
Read
Commented by André Will-Laudien on March 10th, 2023 | 10:15 CET
Defeat cancer! Defence Therapeutics, BioNTech, Morphosys, Bayer - These biotechs are close
The listed biotechnology sector has entered a strong correction phase since the COVID-19 pandemic mode ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Compounding the problem for companies is the significant increase in interest rates for long-term financing. The segment relies on revolving investor capital, but the corresponding risk parameters have been adjusted upward, making some refinancings extremely expensive. Costs are rising, which is leading to renewed price markdowns. However, some companies are convincing through their innovative strength and have recently outperformed the market. We take a closer look at the blockbuster stocks.
Read
Commented by André Will-Laudien on February 14th, 2023 | 15:54 CET
Election winners in the fight against cancer! Bayer, Defence Therapeutics, Formycon, Valneva - 300% rises are possible!
In 2021, 18.7 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. Thanks to growing research successes, however, there is hope that biotechnology will make it much more likely that sufferers will survive. It is a matter of developing suitable active substances or launching modern therapies. Recently, mRNA technology has also been making a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. Which shares are currently in the spotlight?
Read